You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康寧傑瑞(09966.HK)發布三項II期臨床試驗結果 KN046療效顯著
康寧傑瑞(09966.HK)公布,近日已於2022年SABCS大會上發布三項II期臨床試驗結果,包括KN046聯合白蛋白紫杉醇治療轉移性TNBC的II期臨床試驗研究結果;KN026聯合多西他賽一線治療HER2陽性復發或轉移性BC的II期臨床試驗研究結果;及KN026聯合多西他賽用於HER2陽性早期或局部晚期BC的新輔助治療的II期臨床試驗初步結果。 該等臨床試驗的結果初步顯示KN046具有良好安全性及顯著療效。公司認為,KN046有望成為突破性腫瘤免疫特效藥。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account